HiFiBiO Therapeutics

In advance of International Women’s Day, we celebrate the incredible women who are making a difference at HiFiBiO Therapeutics and our clinical partner organizations across the globe. These female scientists and leaders are at the forefront of advancing a diverse pipeline of drug candidates. Their dedication and expertise have been instrumental in developing best-in-class and first-in-class antibodies, offering the potential to deliver transformative treatments to patients with critical unmet needs. We are grateful for their ongoing contributions and the lasting impact they are making on the future of healthcare.? ? #InternationalWomensDay #IWD2025 #womeninSTEM #women?

March is #ColorectalCancerAwarenessMonth. ? Colorectal cancer is the second leading cause of cancer death in the United States, with around 150,000 diagnoses and more than 50,000 deaths in 2024. Screening via colonoscopy can help prevent and detect this cancer. In recent years, there has been an increase in early-onset colorectal cancer where it is diagnosed in people under the age of 50 (Colorectal Cancer | Cancer Awareness Months | AACR). ? HiFiBiO Therapeutics is dedicated to develop curative immunotherapy for each and every patient. Through our proprietary single cell-powered Drug Intelligence Science (DIS?) translational platform, we have advanced a diverse therapeutic pipeline for cancers with high unmet need. Our best-in-class BTLA antagonist HFB200603 (NCT05789069) has shown early efficacy in colorectal cancer patients, particularly those with microsatellite stable (MSS) colorectal cancers. #immunooncology #oncology #innovation #immunotherapy #antibody

Today is #WorldCancerDay. Join HiFiBiO to raise awareness and take steps toward better cancer prevention and treatment options. According to AACR, about 2 million new cases of cancer were diagnosed in the U.S. in 2024, and more than 600,000 people died from cancer. The public health burden posed by cancer will continue to grow, pushing for more effective prevention, detection, and treatment strategies. (Cancer in 2024 | AACR Cancer Progress Report 2024) We're applying our proprietary Drug Intelligence Science (DIS?) single cell translational platform to enhance the clinical response of immunotherapies in high unmet-need cancers. Currently, HiFiBiO is advancing two lead immuno-oncology programs through Phase 1a/1b clinical trials: the first-in-class TNFR2 agonist monoclonal antibody emunkitug (HFB200301, NCT05238883) and the best-in-class BTLA antagonist monoclonal antibody HFB200603 (NCT05789069). #DrugIntelligenceScience #immunooncology #oncology #innovation #immunotherapy #antibody

As the holiday season approaches, we want to take a moment to share our heartfelt gratitude with everyone who has supported us throughout the year. Together, we’ve achieved significant milestones, including advancements in our three Phase I immuno-oncology therapies and progress across our robust pipeline of inflammation and immunology (I&I) programs—highlighted by IND clearance for our best-in-class BTLA agonist to treat I&I diseases. Thank you for being an essential part of our mission to develop transformative immunotherapies for patients worldwide. Wishing you a joyful holiday season and a bright, prosperous New Year!

We are thrilled to have our very own Liang Schweizer join the Life Science Cares Boston Board of Advisors! We are proud to see our leaders not only passionate about developing HiFiBiO’s lead candidates through clinical trials for patients with high unmet needs, but also care deeply about the community around us.?

HiFiBiO Therapeutics Founder, Chairperson, and CEO Liang Schweizer sits down with NYSE Floor Talk to discuss how HiFiBiO Therapeutics is revolutionizing the development of immunotherapies through AI/ML to enhance the probability of success in patients suffering from cancer and I&I diseases.?? ?? #HiFiBiOWay #Interview?#Immunotherapies?#Innovation?#NYSEFloorTalk

Thank you Spencer Huggett for showcasing our unique AI/ML-driven translational approach towards immunotherapy development!

We're so excited for #SITC2024! If you are also attending, don't forget to stop by our two posters showcasing our AI/ML clinical technology in two Phase 1 novel immuno-oncology programs: a first-in-class TNFR2 agonist HFB200301 (NCT05238883) and a best-in-class BTLA antagonist HFB200603 (NCT05789069).? ? Learn more about these two programs and their therapeutic potential, even in IO refractory tumors! ? Can’t join in person? Our posters are now available on our website. https://lnkd.in/eJnxmUhw #cancer #aiandml #immunooncology #immunotherapy #innovation #DrugIntelligenceScience #TNFR2 #BTLA

We are thrilled to share that the FDA has cleared our IND application for HFB200604, our first inflammation and immunology program! ? HFB200604 is a best-in-class BTLA agonist monoclonal antibody developed using HiFiBiO’s proprietary Drug Intelligence Science (DIS?) platform. It is designed to restore immune tolerance in a host of autoimmune diseases by stimulating BTLA signaling in immune cells. https://lnkd.in/eSUKhF8P #autoimmune #inflammation #immunology #immunotherapy #innovation #BTLA #antibody #IND #agonist

Attending #SITC2024? Stop by our two posters showcasing our AI/ML clinical technology in two Phase 1 novel immuno-oncology programs: a first-in-class TNFR2 agonist HFB200301 (NCT05238883) and a best-in-class BTLA antagonist HFB200603 (NCT05789069).? ? Learn more about these two programs and their therapeutic potential, even in IO refractory tumors! https://lnkd.in/eJnxmUhw ? #cancer #aiandml #immunooncology #immunotherapy #innovation #DrugIntelligenceScience #TNFR2 #BTLA